Migraine Drugs Market Size, Share, Growth Analysis, By Treatment Class (Acute/Abortive Treatment, Preventive/Prophylactic Treatment), By Therapeutic Class (Triptans, Acetylcholine Inhibitors/Neurotoxins), By Route of Administration (Oral, Injectables), By Region - Industry Forecast 2024-2031.

Region-wise, North America is the dominating region among others and is expected to lead over the forecast period owing to the increasing cases of migraines and higher awareness of drugs among patients and healthcare professionals. This results in elevated demand for efficient treatments. Regional growth is also impacted by the presence of well-developed healthcare infrastructure that facilitates better distribution of migraine medicines and better access to multiple treatments. Also, the existence of a greater number of pharma companies that drive availability and innovations is notably affecting the growth of the market. The key players operating in the region include AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Boehringer Ingelheim, Novartis International AG, and more.

Europe is the fastest-growing region in global migraine drugs market due to the growing cases of migraines and increased rate of diagnosis. Europe holds comparatively increased number of migraine patients and improved diagnostic treatments. This results in higher demand for effective and reliable treatments. Another reason for the regional growth is attributed to well-funded and superior healthcare systems in several countries to aid innovative therapies and migraine treatments. The region also holds a supportive regulatory environment for the approval of novel migraine treatments.